Loading stock…

Corcept Therapeutics Incorporated (CORT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Corcept Therapeutics Incorporated

CORTMarket cap $13BPrice $119.6

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops drugs that treat cortisol-related disorders, including Cushing's syndrome. Its blockbuster Korlym essentially owns the market it created, giving Corcept a near-monopoly on a rare but lucrative corner of endocrine medicine.

In Bastion Portfolios?

52W Return+52%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+24%9

Revenue Forecast

Rev CAGR (1y)+51%10

Rev CAGR (3y)+39%10

Rev CAGR (5y)+33%10

Earnings Forecast

EPS Growth Y+1+135%10

EPS Growth Y+2+125%10

EPS Growth Y+3+33%9

Quality

Margins

EBIT Margin1%2

Net Income Margin7%4

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA-48.710

Efficiency

ROE8%4

ROA7%7

Earnings Stability77

GEAR+STRONG78

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)214

P/E Ratio (Forward 3y)183

P/BV18.31

EV Multiples

EV/EBITDA Fwd831

EV/EBIT Fwd471

Yield

Free Cash Flow Yield0.8%3

Dividend Yieldna–

Momentum

Short term

1 month return+5%9

3 month return+29%10

YTD return+244%10

Mid term

Price vs 52wHigh95%10

1 year return+35%8

Long term

3 year return+353%10

5 year return+488%10

Risk Shield

Price Risk

Beta0.48

Volatility95%1

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield0.8%3

Quality

ROCE1%2

Earnings Stability77

Net Debt/EBITDA-48.710

02Growth

Is it actually growing, and how fast?

CORTCorcept Therapeutics

Revenue FY25$761M

GROWTH RATING↗

VERY STRONG99 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+24%9

Revenue, next 1Y+51%10

Revenue, next 3Y, CAGR+39%10

Revenue, next 5Y, CAGR+33%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+135%10

EPS growth, FY27E+125%10

EPS growth, FY28E+33%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 99% of companies worldwide.

Revenue grew 24%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 39%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 24%/yr over the last 3 years and is set to grow 39%/yr from here.

The runway holds up: revenue is set to grow 33%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 125%/yr vs revenue 39%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG99 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+29%10

YTD return+244%10

MID & LONG-TERM▾SCORE

% of 52-week high95%10

1-year return+35%8

3-year return+353%10

5-year return+488%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +353% over three years and +488% over five, ahead of 90% of the market.

It's up 35% over the past year, now 5% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+29%) and so far this year (+244%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Corcept Therapeutics Incorporated. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CORTCorcept Therapeutics

Revenue FY25$761M

GROWTH RATING↗

VERY STRONG99 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+24%9

Revenue, next 1Y+51%10

Revenue, next 3Y, CAGR+39%10

Revenue, next 5Y, CAGR+33%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+135%10

EPS growth, FY27E+125%10

EPS growth, FY28E+33%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 99% of companies worldwide.

Revenue grew 24%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 39%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 24%/yr over the last 3 years and is set to grow 39%/yr from here.

The runway holds up: revenue is set to grow 33%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 125%/yr vs revenue 39%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG99 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+29%10

YTD return+244%10

MID & LONG-TERM▾SCORE

% of 52-week high95%10

1-year return+35%8

3-year return+353%10

5-year return+488%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +353% over three years and +488% over five, ahead of 90% of the market.

It's up 35% over the past year, now 5% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+29%) and so far this year (+244%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Corcept Therapeutics Incorporated. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community